Literature DB >> 11147489

A perspective on monoclonal antibody therapy: where we have been and where we are going.

R Levy1.   

Abstract

The history of monoclonal antibody therapy for cancer includes many promising beginnings, a vast number of detours, and now a major success--perhaps soon to be joined by several more. Years of research by hundreds of investigators worldwide have led to a growing understanding of the principles that underlie successful monoclonal antibody therapy and that can be used to create new antibody-based agents. However, there are many remaining uncertainties about this mode of therapy, even for those agents that have already joined our therapeutic armamentarium. Several key questions will be identified and used to suggest avenues for future research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147489     DOI: 10.1016/s0037-1963(00)90059-3

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

1.  Recruiting dendritic cells to improve antibody therapy of cancer.

Authors:  Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

2.  Innovative strategies in lymphoma therapy.

Authors:  Ulrich Jäger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 3.  Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.

Authors:  M V Dhodapkar; K M Dhodapkar; A K Palucka
Journal:  Cell Death Differ       Date:  2007-10-19       Impact factor: 15.828

4.  In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids.

Authors:  Uri Galili; Mark R Albertini; Paul M Sondel; Kim Wigglesworth; Mary Sullivan; Giles F Whalen
Journal:  Cancers (Basel)       Date:  2010-05-04       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.